Cargando…
DARPP-32 promotes ERBB3-mediated resistance to molecular targeted therapy in EGFR-mutated lung adenocarcinoma
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)-refractory lung adenocarcinoma (LUAD) progression is a major clinical problem. New approaches to predict and prevent acquired resistance to EGFR TKIs are urgently needed. Here, we show that dopamine and cyclic AMP-regulated phos...
Autores principales: | Alam, Sk. Kayum, Zhang, Yongchang, Wang, Li, Zhu, Zhu, Hernandez, Christina E., Zhou, Yuling, Yang, Nong, Lei, Jian, Chen, Xiaoyan, Zeng, Liang, Klein, Mark A., Hoeppner, Luke H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8529229/ https://www.ncbi.nlm.nih.gov/pubmed/34675407 http://dx.doi.org/10.1038/s41388-021-02028-5 |
Ejemplares similares
-
IKKα promotes lung adenocarcinoma growth through ERK signaling activation via DARPP-32-mediated inhibition of PP1 activity
por: Alam, Sk. Kayum, et al.
Publicado: (2023) -
ASCL1-regulated DARPP-32 and t-DARPP stimulate small cell lung cancer growth and neuroendocrine tumour cell proliferation
por: Alam, Sk. Kayum, et al.
Publicado: (2020) -
DARPP-32 and t-DARPP promote non-small cell lung cancer growth through regulation of IKKα-dependent cell migration
por: Alam, Sk. Kayum, et al.
Publicado: (2018) -
DARPP-32: from neurotransmission to cancer
por: Belkhiri, Abbes, et al.
Publicado: (2016) -
Darpp-32 and t-Darpp are differentially expressed in normal and malignant mouse mammary tissue
por: Christenson, Jessica L, et al.
Publicado: (2014)